Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in moderate to severe Systemic Lupus Erythematosus
NCT07438496Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of nipocalimab in systemic lupus erythematosus (SLE), sponsored by Janssen Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07438496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438496.